Shenzhen

The trials here

What the 19 trials at this site are about, from their registry records.

Conditions

• Chronic myeloid leukaemia3 trials
• IgA nephropathy3 trials
• Lupus (SLE)3 trials
• Sjögren's disease3 trials
• Ankylosing spondylitis1 trial
• Chronic kidney disease1 trial
• Familial hypercholesterolaemia1 trial
• Immune thrombocytopenia (ITP)1 trial
• Multiple sclerosis1 trial
• Myasthenia gravis1 trial
• Myelodysplastic syndromes1 trial
• Psoriasis1 trial
• and 1 more

Phase

• Phase 314 trials
• Phase 22 trials
• Phase 41 trial

Status

• Active, not recruiting8 trials
• Completed7 trials
• Recruiting2 trials
• Terminated2 trials

Lead sponsor

• Novartis Pharmaceuticals19 trials

Running trials

• Recruiting

  Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden

  NCT07621809· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Recruiting

  Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

  NCT06711887· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

  NCT06517758· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

  NCT05985915· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Zigakibart in Adults With IgA Nephropathy

  NCT05852938· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

  NCT05653349· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

  NCT05399992· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

  NCT05126277· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

  NCT04971226· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

  NCT04557462· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lupus (SLE)1 recruiting
• Sjögren's disease1 recruiting

Closed trials

• Terminated

  Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

  NCT05268289· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

  NCT05350072· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in China

  NCT05199571· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)

  NCT05089656· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

  NCT04795427· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China

  NCT04894890· Novartis Pharmaceuticals· Source

• Completed

  Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis

  NCT04732117· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

  NCT04578834· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Phase 3· Novartis Pharmaceuticals· Source